Advances in acute lymphoblastic leukemia in adults

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 692-699

  Ribera, Josep Maria ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

adult acute lymphoblastic leukemia; prognosis; therapy

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYDROCORTISONE; IMATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM LEUKEMIA; GERIATRIC PATIENT; HUMAN; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ADULT; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 80054101852     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834bb854     Document Type: Review

References (88)

1. Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park) 2011; 25:328-335.
2. Litzow MR. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs 2011; 71:415-442.
3. Narayanan S, Shami PJ. Treatment of acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 2011. [Epub ahead of print]
4. Schafer ES, Hunger SP. Medscape. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.NatRev ClinOncol 2011;8:417-424.
5. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29:532-543.
6. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010; 116:1165-1176.
7. Fullmer A, O'Brien S, Kantarjian H, Jabbour E.Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 2010; 15:1-11.
8. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 2010; 150:389-405.
9. Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010; 115: 206-214; Erratum in Blood 2010; 116:1017.
10. Heesch S, Goekbuget N, Stroux A, et al. Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 2010; 95:942-949.
11. Xu B, Song X, Yip NC, et al. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology 2010; 15:74-80.
12. Kü hnl A, Gö kbuget N, Stroux A, et al. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 2010; 115:3737-3744.
13. Bonnet M, Loosveld M, Montpellier B, et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood 2011; 117:6650-6659.
14. Burmeister T, Gö kbuget N, Schwartz S, et al. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica 2010; 95:241-246.
15. Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.Clin Cancer Res 2011; 17:396-400.
16. Usvasalo A, Elonen E, Saarinen-Pihkala UM, et al. Prognostic classification of patients with acute lymphoblastic leukemia by using gene copy number profiles identified from array-based comparative genomic hybridization data. Leuk Res 2010; 34:1476-1482.
17. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:7-12.
18. Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24:521-535.
19. Kikuchi M, Tanaka J, Kondo T, et al. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Int JHematol 2010;92:481-489.
20. Wood WA, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood 2011; 117:5803-5815.
21. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:21-29.
22. Pui CH, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2011; 29:386-391.
23. Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno JA, et al. Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience. Leuk Lymphoma 2011; 52:314-316.
24. Carter A. Will the pediatric regimen work for adolescents with ALL? J Natl Cancer Inst 2010; 102:1308-1309.
25. Haïat S, Marjanovic Z, Lapusan S, et al. Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol. Leuk Res 2011; 35:66-72.
26. Al-Khabori M, Minden MD, Yee KW, et al. Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. Leuk Lymphoma 2010; 51:61-65.
27. Thomas D, O'Brien S, Faderl S, et al. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer 2010; 116:4580-4589.
28. Jinnai I, Sakura T, Tsuzuki M, et al. Intensified consolidation therapy with doseescalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. Int J Hematol 2010; 92:490-502.
29. Labar B, Suciu S, Willemze R, et al. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica 2010; 95:1489-1495.
30. Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 2010; 10:833-839.
31. Goekbuget N, Baumann A, Beck J. PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003. Blood 2010; 116:494a.
32. Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011; 117:238-249.
33. Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011; 152:452-459.
34. Patil S, Coutsouvelis J, Spencer A. Asparaginase in the management of adult acute lymphoblastic leukaemia: is it used appropriately? Cancer Treat Rev 2011; 37:202-207.
35. Domenech C, Thomas X, Chabaud S, et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011; 153:58-65.
36. Baker KS, Ness KK, Weisdorf D, et al. Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia 2010; 24:2039-2047.
37. Paulson K, Szwajcer D, Seftel MD. The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Transfus Apher Sci 2011; 44:197-203.
38. Rowe JM. Interpreting data on transplant selection and outcome in adult acute lymphoblastic leukemia (ALL). Biol Blood Marrow Transplant 2011; 17 (1 Suppl.):S76-S83.
39. Sellar RS, Goldstone AH. Transplants for the old but not for the young? The enigma of adult ALL. Biol Blood Marrow Transplant 2011; 17 (1 Suppl): S71-SS75.
40. Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer 2010; 116:3447-3457.
41. Kako S, Morita S, Sakamaki H, et al. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission that have an HLA-matched sibling donor. Leukemia 2011; 25:259-265.
42. Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trialUKALL XII/ECOG2993. Br JHaematol 2010;148:80-89.
43. Nishiwaki S, Inamoto Y, Sakamaki H, et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010; 116:4368-4375.
44. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653-660.
45. Ferrá C, Sanz J, de la Cámara R, et al. Unrelated transplantation for poorprognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. Biol Blood Marrow Transplant 2010; 16:957-966.
46. Nishiwaki S, Inamoto Y, Imamura M, et al. Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosomenegative acute lymphoblastic leukemia in complete remission. Blood 2011; 117:3698-3699.
47. Horwitz ME. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol 2011; 23:197-202.
48. Marks DI, Wang T, Pé rez WS, et al. The outcome of full-intensity and reducedintensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010; 116:366-374.
49. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116:4439-4443.
50. Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, et al. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant 2010; 45:1095-1101.
51. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosomepositive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011; 117:1583-1594.
52. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2010; 116:3409-3417.
53. Stock W. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 2010; 51:188-198.
54. Ribera JM, Oriol A, Gonzá lez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95:87-95.
55. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28:3644-3652.
56. Mizuta S, Matsuo K, Yagasaki F, et al. Pretransplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011; 25:41-47.
57. Jaso J, Thomas DA, Cunningham K, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer 2011; 117: 4009-4017.
58. Zuo Z, Jones D, Yao H, et al. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol 2010; 23:1524-1534.
59. Nishiwaki S, Miyamura K, Kato C, et al. Impact of posttransplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer Res 2010; 30:2415-2418.
60. Nakasone H, Kanda Y, Takasaki H, et al. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia 2010; 24:1236-1239.
61. Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010; 85:164-170.
62. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph\+) acute lymphoblastic leukemia. Blood 2010; 116:2070-2077.
63. Rousselot P, Cayuela JM, Hayette S. Dasatinib (Sprycel1) and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): kinetic of response, resistance and prognostic significance. Blood 2010; 116:abstract 172.
64. Nguyen T, Dai Y, Attkisson E, et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or-resistant BCR/ABL\+ leukemia cells in vitro and in vivo. Clin Cancer Res 2011; 17:3219-3232.
65. Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res 2010; 34: 1035-1042.
66. Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 2010; 95:324-328.
67. Bachanova V, Sandhu K, Yohe S, et al. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood 2011; 117: 5261-5263.
68. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lmphoblastic leukemia. J Clin Oncol 2010; 28:3880-3889.
69. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20\+ B-lineage standard and high risk patients; results of 263 CD20\+ patients studied prospectively in GMALL Study 07/2003. Blood 2010; 116:170a.
70. Jabbour E, O'Brien SM, Thomas DA, et al. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). J Clin Oncol 2011; 29 (Suppl):abstract 6507.
71. Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011; 71:1374-1384.
72. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-2498.
73. Meijerink JP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010; 23:307-318.
74. Piovan E, Yu J, Real P, et al. Oncogenic AKT signaling negatively regulates glucocorticoid receptor function to promote glucocorticoid resistance in T cell acute lymphoblastic leukemia. Blood 2010; 116:11a.
75. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 2009; 23:1374-1377.
76. Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol 2010; 4:133-141.
77. Marks DI. Treating the 'older' adult with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:13-20.
78. Jabbour E, Thomas D, Cortes J, et al. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 2010; 116:2290-2300.
79. Gökbuget N, Hartog CM, Bassan R, et al. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 2011; 96:238-244.
80. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010; 116:5568-5574.
81. Oriol A, Vives S, Hernández-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive riskadapted trials by the PETHEMA Study Group. Haematologica 2010; 95:589-596.
82. Kantarjian HM, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 2010; 51:475-480.
83. Ueki T, Sumi M, Sato K, et al. Reduced-intensity cord blood transplantation without prior remission induction therapy induces durable remission in adult patients with relapsed acute leukemia after the first allogeneic transplantation. Eur J Haematol 2011; 86:268-271.
84. Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 2010; 151:430-434.
85. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28:4919-4925.
86. Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011; 96:62-68.
87. Paulson K, Kumar R, Ahsanuddin A, Seftel MD. Azacytidine as a novel agent in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma 2011; 52:134-136.
88. Kasner MT. Novel targets for treatment of adult acute lymphocytic leukemia. Curr Hematol Malig Rep 2010; 5:207-212.